Schellenberg Wittmer advised Morimatsu Group, which is listed on the stock exchange of Hong Kong, on the acquisition of the Swiss company Bioengineering AG. Bioengineering AG specializes in the design and construction of tailor-made equipment and services that enhance the efficiency of bioproduction in the biotechnology, novel food and biopharmaceutical sectors.